BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
50-50 joint venture company building first commercial project in Highlands County, Florida
BP and Verenium Corporation announced that its 50-50 joint venture company will operate under the name Vercipia biofuels, and plan to relocate its corporate headquarters to Florida. Vercipia continues to focus on the development of one of the nation's first commercial-scale cellulosic ethanol facilities, located in Highlands County, Florida. The company is also developing a second commercial-scale cellulosic ethanol site in the Gulf Coast region.
Since announcing the formation of the joint venture company in February, Vercipia has applied for and been selected to move forward with due diligence on a Department of Energy (DOE) Loan Guarantee for the Highlands project, which is now underway.
Other news from the department business & finance
These products might interest you

Fully automated hydrogenation reactor BR/H2 by Berghof
Fully automated hydrogenation reactor: Precise and safe hydrogenation at the flick of a switch
Optimised process control with leakage tests, gas consumption measurement and modular expandability

BRC - Berghof Reactor Controller by Berghof
BRC - complete package for data acquisition, storage and control of all process parameters
Touch controllers are easy to use and provide quick access to all important functions

Berghof Reaktortechnologie - Hoch- und Niederdruckreaktoren, Druckbehälter und metallfreie Reaktoren by Berghof
Safe high- and low-pressure systems for aggressive media
Corrosion-resistant reactors with PTFE lining - individually configurable

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
DataApex will deliver a new OEM version of Clarity Chromatography Software for Shimadzu China
Novartis' leukemia drug Glivec® approved in Switzerland

Number of Participations in Startups Stagnating - In almost 40 percent of the companies, the willingness to take risks is low or virtually nonexistent
Schering-Plough Completes Acquisition of Most NeoGenesis' Assets
Category:Heterocyclic_compounds_(3_rings)
